Form 4: TNF Pharmaceuticals Interim CFO Acquires Stock Options

Ian Rhodes, Interim CFO of TNF Pharmaceuticals, acquired 25,000 employee stock options on April 17, 2025.

Summary

• On April 18, 2025, Ian Rhodes, the Interim CFO of TNF Pharmaceuticals, filed a Form 4.
• The form reports the acquisition of 25,000 employee stock options on April 17, 2025.
• The exercise price of these options is $0.1832.
• The options vest on April 18, 2025, and expire on April 16, 2035.
• The options are for 25,000 shares of common stock.
• The stock options are subject to expiration if the employment of the Reporting Person is terminated.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine filing related to stock option grants. The CFO's acquisition of options is mildly positive, suggesting confidence, but it's not a major event.

Positives

• The acquisition of stock options by the Interim CFO could indicate confidence in the company's future performance.

Risks

• The stock options are subject to expiration if the employment of the Reporting Person is terminated.

Industry Context

Form 4 filings are a standard part of regulatory compliance for company insiders and provide transparency into their transactions in the company's securities.

Stakeholder Impact

• The acquisition of stock options by the Interim CFO could be viewed positively by shareholders as it aligns management's interests with theirs.

Key Dates

Keywords

stock options, Form 4, TNF Pharmaceuticals, Ian Rhodes, Interim CFO, acquisition, TNFA